N,N-dimethyltryptamine (DMT) is a psychedelic compound under investigation for a range of therapeutic uses. One avenue of research is being pursued by Algernon Pharmaceuticals, who are investigating whether sub-hallucinogenic DMT doses could help to protect and repair the brain in the hours after a stroke.
People may not have to microdose psychedelics to feel their wellbeing benefits – they just have to believe they’ve microdosed them, according to researchers from Imperial College London.
The biotech and life sciences company Mydecine Innovations Group recently announced it had completed its first commercial export of legal psychedelic psilocybin mushrooms from Jamaica to Canada. Technology Networks caught up with the company's chief scientific officer, Rob Roscow, to find out more.
The researchers found MDMA-assisted psychotherapy to have a particularly “impressive effect size” in reducing PTSD symptoms. But they say more studies will be needed before the drug can be recommended for clinical practice.
The team at Complex Biotech Discovery Ventures, based in Vancouver, intend to expand the current knowledge base for the psilocybin mushrooms and create a compound library describing the major and minor chemical constituents that make up these mushrooms.
Albert Garcia-Romeu, an assistant professor at the Center for Psychedelic and Consciousness Research at Johns Hopkins University, walks Analytical Cannabis through the past, present, and future of psychedelic research.
Psilocybin’s emergence as a valuable tool for mental health research has been a huge breakthrough for the field. But how do researchers get their hands on this heavily regulated substance? We talked to Tim Moore, CEO of Havn Life Sciences, a company that produces psychoactive compounds from plants and fungi, to find out more.